ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor’s four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. If you purchased shares of Capricor between October 9, 2024 and July 10, 2025, and exp ...